GlassScriptPhysician profile
Milton S Costa
NPI 1629142674
$4,065.25
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $770 · 2021: $1,471 · 2022: $795.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $472.30 | 2019-2022 | |
| Lilly USA, LLC | $403.73 | 2019-2022 | |
| Amgen INC. | $359.87 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $345.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.24 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.51 | 2021-2022 | |
| Pfizer INC. | $169.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $155.93 | 2019-2022 | |
| Esperion Therapeutics, INC. | $147.50 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $121.99 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.52 | 2021-2022 | |
| Glaxosmithkline, LLC. | $105.90 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $105.48 | 2021 | |
| Abbvie INC. | $95.49 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $90.49 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $90.25 | 2021-2022 | |
| Amarin Pharma, INC. | $83.68 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $82.49 | 2021-2022 | |
| Astellas Pharma US INC | $78.19 | 2019-2020 | |
| Abbott Laboratories | $66.92 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.98 | 2019-2020 | |
| Radius Health, INC. | $46.43 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.33 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $38.12 | 2022 | |
| Eisai INC. | $37.71 | 2020-2021 | |
| Shire North American Group INC | $29.44 | 2019 | |
| Optinose US, INC. | $27.11 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $25.42 | 2019 | |
| Horizon Therapeutics Plc | $24.25 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.64 | 2019 | |
| Phadia US INC. | $16.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.22 | 2021 | |
| Genentech USA, INC. | $14.68 | 2020 | |
| Mylan Specialty L.P. | $13.97 | 2020 | |
| Hikma Pharmaceuticals USA | $12.75 | 2019 | |
| Allergan, INC. | $12.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.